FilingReader Intelligence
Sino Biopharmaceutical expects $300m milestone payment from Merck
July 30, 2025 at 11:01 AM UTC•By FilingReader AI
Sino Biopharmaceutical Limited expects to receive a $300m technology transfer milestone payment from Merck & Co for the LM-299 "PD-1/VEGF Bispecific Antibody" project.
Merck confirmed completion of the LM-299 technology transfer in July and anticipates recognizing the payment in Q3 2025. This follows a 2024 global exclusive licensing agreement including a $588m upfront payment and potential milestones up to $2.7bn.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:1177•Hong Kong Exchange
News Alerts
Get instant email alerts when Sino Biopharmaceutical publishes news
Free account required • Unsubscribe anytime